Evidence map›Paper›PMID 42589622›Full record

ArticleInternational journal of molecular sciences2026

Experimental Analysis of HPV16 L1/L2 Chimeric VLP Internalization by Human Peripheral Blood Leukocytes.

Aurora Marques Cianciarullo, Dirce Sakauchi, Erica Akemi Kavati Sasaki, Tania Matiko Hosoda, Primavera Borelli, Willy Beçak

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aurora Marques CianciarulloLaboratory of Genetics, Butantan Institute, Secretary of Sao Paulo State for Health, 1500 Dr. Vital Brazil Avenue, Sao Paulo 05503-900, Brazil.ORCID 0000-0002-0676-9190
Dirce SakauchiLaboratory of Genetics, Butantan Institute, Secretary of Sao Paulo State for Health, 1500 Dr. Vital Brazil Avenue, Sao Paulo 05503-900, Brazil.
Erica Akemi Kavati SasakiLaboratory of Genetics, Butantan Institute, Secretary of Sao Paulo State for Health, 1500 Dr. Vital Brazil Avenue, Sao Paulo 05503-900, Brazil.
Tania Matiko HosodaLaboratory of Genetics, Butantan Institute, Secretary of Sao Paulo State for Health, 1500 Dr. Vital Brazil Avenue, Sao Paulo 05503-900, Brazil.
Primavera BorelliLaboratory of Experimental and Clinical Hematology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, 580 B17 Prof Lineu Prestes Avenue, University City, Sao Paulo 05508-900, Brazil.
Willy BeçakLaboratory of Genetics, Butantan Institute, Secretary of Sao Paulo State for Health, 1500 Dr. Vital Brazil Avenue, Sao Paulo 05503-900, Brazil.

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP Proc. No. 2004/15122-5 - Responsible: Prof. Dr. Aurora M. Cianciarullo
6 · The paper itself

Abstract

Human papillomavirus type 16 (HPV16) is a major etiological agent of cervical and other epithelial cancers, yet the mechanisms underlying host-pathogen interactions remain incompletely understood. In this study, we investigated the responses of human peripheral blood leukocytes to engineered HPV16 L1/L2 chimeric virus-like particles (VLPs), produced in suspension by HEK 293-F cells. These VLPs were designed to mimic native viral structures while incorporating chimeric features that enhance stability and immunogenicity. Through experimental assays, we characterized leukocyte engagement, primarily involving leukocyte phenotyping, VLP internalization, confocal colocalization, and endocytic pathway analyses. We demonstrated that recombinant L1/L2 proteins assembled into structured VLPs capable of interacting with mononuclear cells, including lymphocytes and monocytes, but not with polymorphonuclear cells, such as neutrophils, eosinophils and basophils. Uptake occurred via the CD71 transferrin receptor-mediated pathway, in addition to other endocytic routes analyzed, as confirmed by blockage assays using chlorpromazine, rCTB, filipin, nystatin, liquemine, and sodium azide. Confocal colocalization and endocytic pathway analyses further supported receptor-mediated uptake. These findings demonstrate that HPV16 L1/L2 chimeric VLPs interact with and are internalized by human peripheral blood mononuclear cells through CD71-associated and other endocytic pathways. The study provides new insights into HPV16 VLP-leukocyte interactions and contributes to a better understanding of the cellular mechanisms involved in VLP uptake, which may be relevant for future studies on HPV biology and VLP-based vaccine development.

Indexed as

Capsid ProteinsHuman papillomavirus 16Leukocytes, MononuclearOncogene Proteins, ViralVirus InternalizationAntigens, CDEndocytosisHEK293 CellsHumansReceptors, TransferrinRecombinant Fusion ProteinsAntigens, CDCapsid ProteinsCD71 antigenL1 protein, Human papillomavirus type 16L2 protein, Human papillomavirus type 16Oncogene Proteins, ViralReceptors, TransferrinRecombinant Fusion Proteinscancer risk factorschimeric VLP uptake by lymphocytesHPV16 L1/L2 chimeric VLPshuman leukocytesimmunityinfectious diseasesmembrane receptorsmolecular engineeringmolecular virologymononuclear cellsVLP-host leukocyte internalization

Identifiers

PMID42589622
PMCPMC13467160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.